NCT01601808View on ClinicalTrials.gov

Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

October 10, 2011

Primary Completion Date

September 5, 2018

Study Completion Date

September 5, 2018

Conditions
Pancreatic Cancer
Interventions
DRUG

Placebo

Orally once a day, continuously throughout the study

DRUG

Caprelsa (vandetanib)

Orally once a daily, continuously throughout the study.

Trial Locations (14)

BT9 7AB

Belfast City Hospital, Belfast

BH7 7DW

The Royal Bournemouth Hospital, Bournemouth

BS2 8ED

Bristol Haematology and Oncology Centre, Bristol

GU2 7XX

Royal Surrey County Hospital, Guildford

CH63 4JY

Clatterbridge Centre for Oncology, Liverpool

L69 3GA

Royal Liverpool University Hospital, Liverpool

EC1A 7BE

St Bartholomew's Hospital, London

SE1 9RT

Guys & St Thomas Hospital, London

SW3 6JJ

Royal Marsden Hospital, London

M20 4BX

The Christie Hospital, Manchester

TS4 3BW

James Cook University Hospital, Middlesbrough

NE7 7DN

Freeman Hospital, Newcastle

NG5 1PB

Nottingham City Hospital, Nottingham

S10 2SJ

Weston Park Hospital, Sheffield

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University of Liverpool

OTHER